Health Care and Biotech

Concerns about M2’s accounting methods. Potential for health reforms, a look at bank impairment rates and fund managers surveyed.

Moelis is excited about the outlook for TFS Corp’s Indian sandalwood plantations and expects the company to become the sole global provider of this precious oil.

A new specialist medical device stock graces the ASX boards and brokers are bullish about the outlook.

Brokers were disappointed with Cochlear’s first half results and believe the positive aspects were hampered by a list of unanswered questions.

ResMed continues to suffer from weak top line growth and brokers vary as to the extent to which they think this will persist.

A weaker Australian dollar looks to be the key benefit to Australia’s heath care sector as first half reporting approaches.

AllianceBernstein thinks investors should heed the growing trend of emerging markets following western lifestyles.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. After a highly successful capital raising and solid price surge, Vision Eye’s more subdued earnings outlook has prompted a downgrade from Bell Potter.

Moelis has taken a look at the portfolio of products waiting in the wings at Mayne Pharma and considers there is more upside for the stock.

Oz consumer sentiment is improving but is it enough to ensure a strong Christmas? There’s softness in life insurance, improvement in the housing market and modest advertising growth.